These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38626241)

  • 1. Amoxicillin-clavulanate Breakpoints Against Enterobacterales: Rationale for Revision by the Clinical and Laboratory Standards Institute.
    Narayanan N; Mathers AJ; Wenzler E; Moore NM; Giske CG; Mendes RE; Edelstein PH
    Clin Infect Dis; 2024 Apr; ():. PubMed ID: 38626241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Enterobacterales.
    Tamma PD; Harris PNA; Mathers AJ; Wenzler E; Humphries RM
    Clin Infect Dis; 2023 Nov; 77(11):1585-1590. PubMed ID: 36001445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria.
    Asín E; Isla A; Canut A; Rodríguez Gascón A
    Int J Antimicrob Agents; 2012 Oct; 40(4):313-22. PubMed ID: 22921422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute Breakpoints.
    Gupta V; Yu KC; Pogue JM; Watts JA; Clancy CJ
    Microbiol Spectr; 2022 Jun; 10(3):e0115822. PubMed ID: 35638777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M; Browne FA; Jacobs MR; Appelbaum PC
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally Administered Amoxicillin/Clavulanate: Current Role in Outpatient Therapy.
    Veeraraghavan B; Bakthavatchalam YD; Sahni RD
    Infect Dis Ther; 2021 Mar; 10(1):15-25. PubMed ID: 33306184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amoxicillin/clavulanate Breakpoints Against Haemophilus influenzae: Rationale for Revision by the Clinical and Laboratory Standards Institute.
    Narayanan N; Mathers AJ; Wenzler E; Moore NM; Giske CG; Mendes RE; Edelstein PH
    Clin Infect Dis; 2024 May; ():. PubMed ID: 38709848
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antimicrobial Susceptibility of Pathogenic Gram-positive Anaerobic Cocci: Data of a University Hospital in Turkey].
    Akgül Ö; Söyletir G; Ülger Toprak N
    Mikrobiyol Bul; 2020 Jul; 54(3):404-417. PubMed ID: 32755517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results from the Survey of Antibiotic Resistance (SOAR) 2015-18 in Tunisia, Kenya and Morocco: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Hammami A; Mezghani Maalej S; Ayed NB; Revathi G; Zerouali K; Elmdaghri N; Gachii AK; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i2-i18. PubMed ID: 32337595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Turkey: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Tunger A; Sancak B; Bıçakçıgil A; Altun B; Aktas Z; Kayacan C; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i88-i99. PubMed ID: 32337598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers.
    Sader HS; Mendes RE; Kimbrough JH; Kantro V; Castanheira M
    Open Forum Infect Dis; 2023 Feb; 10(2):ofad058. PubMed ID: 36861086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Russia.
    Torumkuney D; Mayanskiy N; Edelstein M; Sidorenko S; Kozhevin R; Morrissey I
    J Antimicrob Chemother; 2018 Apr; 73(suppl_5):v14-v21. PubMed ID: 29659881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results from the Survey of Antibiotic Resistance (SOAR) 2016-17 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Bratus E; Yuvko O; Pertseva T; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i100-i111. PubMed ID: 32337596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of Changes to the Clinical and Laboratory Standards Institute
    Humphries R; Bobenchik AM; Hindler JA; Schuetz AN
    J Clin Microbiol; 2021 Nov; 59(12):e0021321. PubMed ID: 34550809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from the Survey of Antibiotic Resistance (SOAR) 2009-11 in Vietnam.
    Van PH; Binh PT; Minh NH; Morrissey I; Torumkuney D
    J Antimicrob Chemother; 2016 May; 71 Suppl 1(Suppl 1):i93-102. PubMed ID: 27048586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Setting Antimicrobial Susceptibility Testing Breakpoints: A Primer for Pediatric Infectious Diseases Specialists on the Clinical and Laboratory Standards Institute Approach.
    Pierce VM; Mathers AJ
    J Pediatric Infect Dis Soc; 2022 Feb; 11(2):73-80. PubMed ID: 34888640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute.
    Satlin MJ; Nicolau DP; Humphries RM; Kuti JL; Campeau SA; Lewis Ii JS; Weinstein MP; Jorgensen JH
    Clin Infect Dis; 2020 Mar; 70(6):1240-1246. PubMed ID: 31504338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories.
    Humphries RM; Abbott AN; Hindler JA
    J Clin Microbiol; 2019 Jun; 57(6):. PubMed ID: 30971460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    Torumkuney D; Anwar S; Nizamuddin S; Malik N; Morrissey I
    J Antimicrob Chemother; 2020 Apr; 75(Suppl 1):i76-i87. PubMed ID: 32337594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revision of fluoroquinolone breakpoints used for interpretation of antimicrobial susceptibility testing of canine bacterial isolates.
    Papich MG; Gunnett LA; Lubbers BV
    Am J Vet Res; 2023 Nov; 84(11):. PubMed ID: 37673214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.